• Nonnarcotic analgesics

Xaracoll Generic Name & Formulations

General Description

Bupivacaine HCl 100mg (equivalent to 88.8mg bupivacaine) and purified Type I collagen 75mg; per implant.

Pharmacological Class

Local anesthetic (amide-type).

How Supplied

Pouches (3×100mg implants)—4, 10

Generic Availability


Xaracoll Indications


For placement into the surgical site to produce postsurgical analgesia for up to 24hrs following open inguinal hernia repair.

Limitations of Use

Safety and efficacy not established in other surgical procedures, including orthopedic and boney procedures.

Xaracoll Dosage and Administration


See full labeling. For single-dose administration only. Each implant should be cut in half prior to placement into the surgical site. Place 300mg (3×100mg implants) into the surgical site dry (3 halves below the site of mesh placement and 3 halves just below the skin closure). Maximum dose: 300mg/patient.


Not established.

Xaracoll Contraindications


Obstetrical paracervical block anesthesia.

Xaracoll Boxed Warnings

Not Applicable

Xaracoll Warnings/Precautions


To be administered under the supervision of experienced clinicians. Have resuscitative equipment and medical personnel readily available. Monitor cardiovascular and respiratory vital signs, and patient's state of consciousness after administration. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor closely; consider removal of implants and discontinue any oxidizing agents if occurs. Cardiovascular dysfunction (eg, hypotension, heart block); monitor closely for BP, HR, and ECG changes. Risk of delayed bone healing with unapproved use. Renal or moderate to severe hepatic impairment: monitor for toxicity. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

Xaracoll Pharmacokinetics

See Literature

Xaracoll Interactions


Avoid additional local anesthetics within 96hrs following implantation; if unavoidable, monitor for neurologic and cardiovascular effects. Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others (eg, acetaminophen, metoclopramide, quinine, sulfasalazine).

Xaracoll Adverse Reactions

Adverse Reactions

Incision site swelling, dysgeusia, headache, tremor, vision blurred, seroma, scrotal swelling, pyrexia, hypoesthesia oral, post procedural discharge; CNS toxicity (eg, excitation, depression, restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth/lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, drowsiness), cardiac disorders, neurologic effects, allergic-type reactions.

Xaracoll Clinical Trials

See Literature

Xaracoll Note

Not Applicable

Xaracoll Patient Counseling

See Literature